NCT00166543View on ClinicalTrials.gov

Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Breast Cancer
Interventions
DRUG

TAS-108

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

SRI International
All Listed Sponsors
collaborator

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

lead

SRI International

INDUSTRY